The Technical Analyst
Aclaris Therapeutics Inc [ACRS]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Aclaris Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.82% $1.230
America/New_York / 23 apr 2024 @ 10:07
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 87.24 mill |
| EPS: | -1.270 |
| P/E: | -0.970 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 70.93 mill |
| Avg Daily Volume: | 1.081 mill |
| RATING 2024-04-22 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.970 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -0.970 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.147 - 1.333 ( +/- 7.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Walker Neal | Buy | 9 467 | Common Stock |
| 2024-04-01 | Walker Neal | Sell | 3 224 | Common Stock |
| 2024-04-01 | Walker Neal | Sell | 9 467 | Restricted Stock Units |
| 2024-03-01 | Walker Neal | Buy | 9 466 | Common Stock |
| 2024-03-01 | Walker Neal | Sell | 3 223 | Common Stock |
| INSIDER POWER |
|---|
| 77.36 |
| Last 99 transactions |
| Buy: 2 297 521 | Sell: 311 390 |
Forecast:
11:46 - $1.230
Live Trading Signals (every 1 min)
Forecast
1: 10:16 - $1.237
Forecast 2: 11:06 - $1.236
Forecast 3: 11:46 - $1.230
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.230 (0.82% ) |
| Volume | 0.0624 mill |
| Avg. Vol. | 1.081 mill |
| % of Avg. Vol | 5.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACRS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.175 | N/A | Active |
|---|
ACRS
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Latest Press Releases
2024-04-23 08:00:00 - Press Release
Flare Therapeutics Appoints Douglas Manion, M.d., Frcp (c) As Chief Executive Officer
Cambridge, mass. , april 23, 2024 /prnewswire/ -- flare therapeutics inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of douglas manion, m.d.
2024-02-27 07:00:00 - Press Release
Aclaris Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides A Corporate Update
Wayne, pa., feb. 27, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2023 and provided a corporate update.
2024-01-10 07:00:00 - Press Release
Aclaris Therapeutics Announces Top-line Results From 4-week Phase 2b Trial Of Ati-1777 For Mild To Severe Atopic Dermatitis
- ati-1777 2% bid achieved a statistically significant result in the primary efficacy endpoint at week 4 - - minimal systemic exposure supports “soft” topical jak inhibitor approach - - ati-1777 was well tolerated - wayne, pa., jan. 10, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its phase 2b study of ati-1777, an investigational topical “soft” jak 1/3 inhibitor, in patients with mild to severe atopic dermatitis (ad) (ati-1777-ad-202; nct05432596).
2023-12-19 16:01:00 - Press Release
Aclaris Therapeutics Provides Corporate Update
- ati-1777 phase 2a trial results published in jid innovations - - ati-1777 phase 2b trial topline data anticipated in january 2024 - - aclaris announces reduction in workforce -
2023-12-05 16:01:00 - Press Release
Aclaris Therapeutics Announces Patent License Agreement With Sun Pharma For Alopecia
Wayne, pa., dec. 05, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with sun pharmaceutical industries, inc. (sun pharma).
Latest News
2024-04-05 10:46:41 - Zacks Investment Research
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
2024-03-20 10:41:19 - Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
2024-03-04 13:06:09 - Zacks Investment Research
Aclaris (ACRS) Upgraded to Buy: Here's Why
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-04 10:46:20 - Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
2024-02-27 10:36:07 - Zacks Investment Research
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.41 per share a year ago.
2024-02-13 10:40:22 - Zacks Investment Research
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
2024-01-17 12:16:18 - Zacks Investment Research
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
2024-01-10 13:03:47 - Proactive Investors
Aclaris Therapeutics shares torpedo on underwhelming dermatitis trial results
Aclaris Therapeutics shares plunged more than 24% Wednesday after the company's mild to severe atopic dermatitis (AD) treatment received disappointing topline results. The results from the 4-week Phase 2b trial of its ATI-1777 treatment were not statistically superior to the Phase 2a trial, according to chairman Neal Walker added.
2024-01-04 11:20:18 - Zacks Investment Research
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
2023-12-06 14:48:10 - PennyStocks
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.